Entyvio and Hepatic steatosis - a phase IV clinical study of FDA data

Summary:

Hepatic steatosis is found among people who take Entyvio, especially for people who are female, 20-29 old, have been taking the drug for 2 - 5 years.

The phase IV clinical study analyzes which people take Entyvio and have Hepatic steatosis. It is created by eHealthMe based on reports of 18,116 people who have side effects when taking Entyvio from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 17, 2022

18,116 people reported to have side effects when taking Entyvio.
Among them, 37 people (0.2%) have Hepatic steatosis.


What is Entyvio?

Entyvio has active ingredients of vedolizumab. It is often used in crohn's disease. eHealthMe is studying from 15,592 Entyvio users for its effectiveness, alternative drugs and more.

What is Hepatic steatosis?

Hepatic steatosis (fatty liver disease) is found to be associated with 1,922 drugs and 1,315 conditions by eHealthMe.

Number of Entyvio and Hepatic steatosis reports submitted per year:

Could Entyvio cause Hepatic steatosis?

Time on Entyvio when people have Hepatic steatosis *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 100 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hepatic steatosis when taking Entyvio *:

  • female: 55.56 %
  • male: 44.44 %

Age of people who have Hepatic steatosis when taking Entyvio *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 36.84 %
  • 30-39: 21.05 %
  • 40-49: 10.53 %
  • 50-59: 10.53 %
  • 60+: 21.05 %

Common drugs people take besides Entyvio *:

  1. Humira: 17 people, 45.95%
  2. Xeljanz: 16 people, 43.24%
  3. Remicade: 15 people, 40.54%
  4. Asacol: 11 people, 29.73%
  5. Vitamin B12: 11 people, 29.73%
  6. Nicotinamide: 7 people, 18.92%
  7. Stelara: 6 people, 16.22%
  8. Vitamin D: 6 people, 16.22%
  9. Calcium Pantothenate: 6 people, 16.22%
  10. Prednisolone: 5 people, 13.51%

Common side effects people have besides Hepatic steatosis *:

  1. Diarrhea: 27 people, 72.97%
  2. Abdominal Distension: 26 people, 70.27%
  3. Flatulence (flatus expelled through the anus): 22 people, 59.46%
  4. Abdominal Pain: 21 people, 56.76%
  5. Abdominal Discomfort: 19 people, 51.35%
  6. Nausea (feeling of having an urge to vomit): 19 people, 51.35%
  7. Headache (pain in head): 17 people, 45.95%
  8. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 17 people, 45.95%
  9. Drug Ineffective: 16 people, 43.24%
  10. Malaise (a feeling of general discomfort or uneasiness): 16 people, 43.24%

Common conditions people have *:

  1. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 25 people, 67.57%
  2. High Blood Pressure: 4 people, 10.81%
  3. Back Pain: 3 people, 8.11%
  4. Indigestion: 3 people, 8.11%
  5. Pain: 2 people, 5.41%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 5.41%
  7. Birth Control: 1 person, 2.70%
  8. Blood Glucose Increased: 1 person, 2.70%
  9. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 2.70%
  10. Colitis (inflammation of colon): 1 person, 2.70%

* Approximation only. Some reports may have incomplete information.

Do you take Entyvio and have Hepatic steatosis?

Check whether Hepatic steatosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Hepatic steatosis and when was it recovered:

Expand to all the drugs that have ingredients of vedolizumab:

Alternative drugs to, pros and cons of Entyvio:

Common Entyvio side effects:

Browse all side effects of Entyvio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Hepatic steatosis treatments and more:

COVID vaccines that are related to Hepatic steatosis:

Common drugs associated with Hepatic steatosis:

All the drugs that are associated with Hepatic steatosis:

Common conditions associated with Hepatic steatosis:

All the conditions that are associated with Hepatic steatosis:

How the study uses the data?

The study uses data from the FDA. It is based on vedolizumab (the active ingredients of Entyvio) and Entyvio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: